Antiandrogens
Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Favipiravir
Fluvoxamine
Hydroxychloro..
Iota-carragee..
Ivermectin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Colchicine  COVID-19 treatment studies for Colchicine  C19 studies: Colchicine  Colchicine   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Metformin (meta)
Aspirin (meta) Molnupiravir (meta)
Bamlanivimab (meta) Nigella Sativa (meta)
Bromhexine (meta) Nitazoxanide (meta)
Budesonide (meta) Paxlovid (meta)
Casirivimab/i.. (meta) Povidone-Iod.. (meta)
Colchicine (meta) Probiotics (meta)
Conv. Plasma (meta) Proxalutamide (meta)
Curcumin (meta) Quercetin (meta)
Favipiravir (meta) Remdesivir (meta)
Fluvoxamine (meta) Sotrovimab (meta)
Hydroxychloro.. (meta) Vitamin A (meta)
Iota-carragee.. (meta) Vitamin C (meta)
Ivermectin (meta) Vitamin D (meta)
Melatonin (meta) Zinc (meta)

Other Treatments Global Adoption
 
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Deftereos (RCT) 77% 0.23 [0.03-1.97] death 1/55 4/50 Improvement, RR [CI] Treatment Control Lopes (DB RCT) 80% 0.20 [0.01-4.03] death 0/36 2/36 Brunetti (PSM) 73% 0.27 [0.08-0.89] death 3/33 11/33 Scarsi 85% 0.15 [0.06-0.37] death 122 (n) 140 (n) Salehzadeh (RCT) 23% 0.77 [0.66-0.90] hosp. time 50 (n) 50 (n) Pinzón 35% 0.65 [0.34-1.21] death 14/145 23/156 Sandhu 42% 0.58 [0.40-0.85] death 16/34 63/78 Rodriguez-Nava 6% 0.94 [0.61-1.47] death 16/52 85/261 Tardif (DB RCT) 44% 0.56 [0.19-1.67] death 5/2,235 9/2,253 Recovery C.. (RCT) -1% 1.01 [0.93-1.10] death 1,173/5,610 1,190/5,730 Gaitán-Dua.. (RCT) 19% 0.81 [0.48-1.35] death 22/153 28/161 CT​1 Dorward (RCT) -30% 1.30 [0.42-3.84] hosp./death 6/156 4/133 Tau​2 = 0.08; I​2 = 73.9% Late treatment 31% 0.69 [0.54-0.88] 1,256/8,681 1,419/9,081 31% improvement All studies 31% 0.69 [0.54-0.88] 1,256/8,681 1,419/9,081 31% improvement 12 colchicine COVID-19 studies c19colchicine.com Nov 26, 2021 1 CT: study uses combined treatmentTau​2 = 0.08; I​2 = 73.9%; Z = 3.02 Effect extraction pre-specified Favors colchicine Favors control
Database of all colchicine COVID-19 studies. Submit updates/corrections.
 
Search:  
Restrict:    All    Late
Sep 23
Late Dorward et al., medRxiv, doi:2021.09.20.21263828 (Preprint)
hosp./death, ↑29.8%, p=0.66
Colchicine for COVID-19 in adults in the community (PRINCIPLE): a randomised, controlled, adaptive platform trial
Details   Late treatment RCT with 156 colchicine patients in the UK, showing no significant differences. ISRCTN86534580.
Jul 10
Late Gaitán-Duarte et al., medRxiv, doi:10.1101/2021.07.06.21260085 (Preprint)
death, ↓19.0%, p=0.43
Effectiveness of Rosuvastatin plus Colchicine, Emtricitabine/Tenofovir and a combination of them in Hospitalized Patients with SARS Covid-19
Details   RCT 633 hospitalized patients in Colombia, 153 treated with colchicine + rosuvastatin, not showing statistically significant differences in outcomes. Improved results were seen with the combination of emtricitabine/tenofovir disoproxil + ..
May 18
Late Recovery Collaborative Group, The Lancet Respiratory Medicine, doi:10.1016/S2213-2600(21)00435-5 (preprint 5/18/2021) (Peer Reviewed)
death, ↑1.0%, p=0.77
Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Details   RCT with 5,610 colchicine and 5,730 control patients showing mortality RR 1.01 [0.93-1.10]. Very late stage treatment, mean 9 days after symptom onset. Baseline oxygen requirements unknown (data is provided but combined with "none&qu..
Mar 14
Meta Hariyanto et al., Clinical and Experimental Pharmacology and Physiology, doi:10.1111/1440-1681.13488 (Peer Reviewed) (meta analysis)
meta-analysis
Colchicine treatment can improve outcomes of coronavirus disease 2019 (COVID‐19): A systematic review and meta‐analysis
Details   Meta analysis concluding that colchicine can reduce severity and mortality in COVID‐19 patients, mortality OR 0.43 [0.32-0.58].
Jan 27
Late Tardif et al., The Lancet Respiratory Medicine, doi:10.1016/S2213-2600(21)00222-8 (preprint 1/27) (Peer Reviewed)
death, ↓43.9%, p=0.30
Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial
Details   RCT for relatively low risk outpatients, 2235 treated with colchicine a mean of 5.3 days after the onset of symptoms, and 2253 controls, showing lower mortality, ventilation, and hospitalization with treatment. NCT04322682.
Nov 5
2020
Late Rodriguez-Nava et al., Mayo Clinic Proceedings: Innovations, Quality & Outcomes (Peer Reviewed)
death, ↓5.5%, p=0.87
Clinical characteristics and risk factors for mortality of hospitalized patients with COVID-19 in a community hospital: A retrospective cohort study
Details   Retrospective 313 patients, mostly critical stage and mostly requiring respiratory support. Confounding by indication likely.
Oct 27
2020
Late Sandhu et al., Canadian Journal of Infectious Diseases and Medical Microbiology, doi:10.1155/2020/8865954 (Peer Reviewed)
death, ↓41.7%, p=0.0006
A Case Control Study to Evaluate the Impact of Colchicine on Patients Admitted to the Hospital with Moderate to Severe COVID-19 Infection
Details   Prospective cohort study of hospitalized patients in the USA, 34 treated with colchicine, showing lower mortality and intubation with treatment.
Oct 23
2020
Late Pinzón et al., Research Square, doi:10.21203/rs.3.rs-94922/v1 (Preprint)
death, ↓34.5%, p=0.18
Clinical Outcome of Patients with COVID-19 Pneumonia Treated with Corticosteroids and Colchicine in Colombia
Details   Retrospective 301 pneumonia patients in Colombia showing lower mortality with colchicine treatment.
Sep 21
2020
Late Salehzadeh et al., Research Square, doi:10.21203/rs.3.rs-69374/v1 (Preprint)
hosp. time, ↓22.7%, p=0.001
The Impact of Colchicine on The COVID-19 Patients; A Clinical Trial Study
Details   Open label RCT with 100 hospitalized patients in Iran, 50 treated with colchicine, showing shorter hospitalization time. There were no deaths. IRCT20200418047126N1.
Sep 14
2020
Late Scarsi et al., Annals of the Rheumatic Diseases, doi:10.1136/annrheumdis-2020-217712 (Peer Reviewed)
death, ↓84.9%, p<0.0001
Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome
Details   Retrospective 122 colchicine patients and 140 control patients in Italy, showing lower mortality with treatment.
Sep 14
2020
Late Brunetti et al., J. Clin. Med., 9:9, 2961, doi:10.3390/jcm9092961 (Peer Reviewed)
death, ↓72.7%, p=0.03
Colchicine to Weather the Cytokine Storm in Hospitalized Patients with COVID-19
Details   PSM matched analysis from consecutive hospitalized patients, with 33 colchicine and 33 control matched patients, showing lower mortality with treatment.
Aug 12
2020
Late Lopes et al., RMD Open, doi:10.1136/rmdopen-2020-001455 (preprint 8/12) (Peer Reviewed)
death, ↓80.0%, p=0.49
Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trial
Details   RCT with 36 colchicine and 36 control patients, showing reduced length of hospitalization and oxygen therapy with treatment.
Jun 24
2020
Late Deftereos et al., JAMA Network Open, doi:10.1001/jamanetworkopen.2020.13136 (Peer Reviewed)
death, ↓77.3%, p=0.19
Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019: The GRECCO-19 Randomized Clinical Trial
Details   RCT with 55 patients treated with colchicine and 50 control patients, showing lower mortality and ventilation with treatment. NCT04326790.
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit